Search for: "DOW PHARMACEUTICAL SCIENCES, INC."
Results 61 - 80
of 131
Sort by Relevance
|
Sort by Date
21 Feb 2014, 11:04 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S. [read post]
17 Jan 2014, 8:27 pm
Merrell Dow Pharmaceuticals, Inc., the United States Supreme Court held for the first time that, to be admissible, scientific evidence must be both scientifically valid and properly applicable to the facts at issue in the case. [read post]
17 Jan 2014, 8:27 pm
Merrell Dow Pharmaceuticals, Inc., the United States Supreme Court held for the first time that, to be admissible, scientific evidence must be both scientifically valid and properly applicable to the facts at issue in the case. [read post]
30 Oct 2013, 10:57 am
Myriad Genetics, Inc., 133 S. [read post]
2 Jul 2013, 6:17 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), General Electric Co. v. [read post]
6 Jun 2013, 12:15 am
The doctrine of inherent anticipation (particularly after Schering Co. v Geneva Pharmaceuticals Inc. et Al., commented here - see also, in the UK, Merrell Dow v H N Norton & Co), may lead to similar distortions. [read post]
5 Jun 2013, 5:29 am
Oct. 24, 1996) Merrell Dow Pharms., Inc. v. [read post]
5 May 2013, 12:15 pm
Merrell Dow Pharmaceuticals, Inc. [read post]
11 Mar 2013, 8:30 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, has solidified that trend. [read post]
16 Feb 2013, 7:23 am
Merrell Dow Pharmaceuticals, Inc., 509, U.S. 579 (1993). [read post]
27 Dec 2012, 5:07 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 593-94 (1993) are relevant to the Court’s reliability determination under CRE 702, which is identical to FRE 702. [read post]
24 Dec 2012, 9:58 am
Merrell Dow Pharmaceuticals Inc., 509 U.S. 579 (1993), a case that has been superseded by subsequent cases and a revision to the operative statute, Rule 702. [read post]
24 Nov 2012, 12:38 pm
In addition, Havner requires that a plaintiff show ‘that he or she is similar to [the subjects] in the studies’ and that ‘other plausible causes of the injury or condition that could be negated [are excluded] with reasonable certainty’.40” 347 S.W.3d at 265 (quoting from Merrell Dow Pharmaceuticals, Inc. v. [read post]
5 Sep 2012, 5:26 am
("Intendis") and Dow Pharmaceutical Sciences, Inc. [read post]
20 Aug 2012, 11:04 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)? [read post]
20 Aug 2012, 11:04 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)? [read post]
19 Jul 2012, 4:07 pm
Dow Jones & Co., No. [read post]
10 Jun 2012, 1:09 pm
Merrell Dow Pharms., Inc., 874 F.2d 307, 311 (5th Cir. 1989) (noting that “[o]ne difficulty with epidemiologic studies is that often several factors can cause the same disease. [read post]
14 May 2012, 8:24 am
Perrier Group of America Inc., 986 F. [read post]
18 Apr 2012, 4:40 pm
Ortho Pharmaceutical Corp., 615 F. [read post]
